Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth
Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%.
Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.
Research Highlights The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4–5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights.
In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion.
Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.
Key Features The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeutic areas such as rheumatoid arthritis, cancer, and diabetes, and understand the key challenges in the space.
Key Issues Addressed • What is the current scenario of the biosimilars market in APAC, and how far will it grow? • What are the key factors driving the market, and what are the barriers that need to be resolved? • Which are the key market segments to look out for, and what are the key trends and regulatory aspects? • Who are the key market participants involved, and where do they stand? • What are the factors affecting the biosimilars market in the different regions of APAC, and how will these factors affect the market? • What is the future of the biosimilars market in Asia?
Our reports have been used by over 10K customers, including:
The Global Biosimilars Partnering Terms and Agreements 2010 to 2018 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Biosimilars partnering deals Disclosed headlines, upfronts, milestones and royalties...
172 pages •
By International Market Analysis Research and Consult
• Sep 2018
The biosimilar market reached a value of US$ 2.9 Billion in 2017. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost saving initiatives from governments and third party payers. Catalyzed by these factors, the market...
Biosimilars in Oncology Summary Recent trends in drug development have seen the price of new medicines continually increase, and there is a need for cheaper medicines to achieve global sustainable healthcare.Biologic drugs are some of the most expensive medicines to develop, as they are large complex...
243 pages •
By Global Industry Analysts
• Aug 2018
This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary...
220 pages •
By The Business Research Company
• Jul 2018
Biologics Global Market Opportunities And Strategies By Product Type: Monoclonal Antibodies (mAbs), Therapeutic Proteins and Vaccines; By Region, By Country, With Forecast Until 2021 The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human...
The global biosimilars market projected to grow at a CAGR of 31.7% during the forecast period. The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness,...